Jove
Visualize
Contact Us

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis: An Association With Disease Progression.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Microglia subtypes in acute, subacute, and chronic multiple sclerosis.

Journal of neuropathology and experimental neurology·2023
Same author

Case series: Immune checkpoint inhibitor-induced transverse myelitis.

Frontiers in neurology·2023
Same author

Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome.

European journal of neurology·2022
Same author

Response to treatment in NMOSD: the Australasian experience.

Multiple sclerosis and related disorders·2022
Same author

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis.

Frontiers in neurology·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 1, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Multiple sclerosis: Serum anti-CNS autoantibodies.

John W Prineas1, John D E Parratt2

  • 1Brain and Mind Centre, Department of Medicine, The University of Sydney, Camperdown, NSW, Australia.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 27, 2017
PubMed
Summary

Autoantibodies targeting the central nervous system (CNS) are common in multiple sclerosis (MS) patients, but also appear in other neurological conditions and healthy individuals.

Keywords:
Multiple sclerosisautoimmunitymyelinneuromyelitis opticaoligodendrocytes

More Related Videos

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.3K
Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.8K

Related Experiment Videos

Last Updated: Mar 1, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.3K
Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.8K

Area of Science:

  • Neuroimmunology
  • Autoimmunity

Background:

  • The presence of autoantibodies detectable by indirect immunofluorescence in the serum of multiple sclerosis (MS) patients remains uncertain.
  • Investigating anti-central nervous system (CNS) autoantibodies is crucial for understanding MS pathogenesis.

Purpose of the Study:

  • To determine the presence and specificity of anti-CNS autoantibodies in MS patients using indirect immunofluorescence.
  • To compare the prevalence of these autoantibodies in MS patients versus those with other neurological diseases and healthy controls.

Main Methods:

  • Indirect immunofluorescence was employed to examine sera and cerebrospinal fluid from 106 MS patients, 156 patients with other neurological diseases, and 70 healthy controls.
  • Cryostat sections of paraformaldehyde-fixed rat cerebrum were used as the substrate for antibody detection.

Main Results:

  • Autoantibodies recognizing over 30 CNS structures were found in 28% of MS cases.
  • Similar autoantibodies were frequently detected in patients with other neurological diseases and even in healthy controls.
  • Novel anti-CNS autoantibodies targeting specific interneurons were identified in both healthy and diseased subjects.

Conclusions:

  • Diverse anti-CNS autoantibodies are prevalent in MS patients but are not exclusive to this condition.
  • The findings do not support the hypothesis that serum anti-myelin or anti-oligodendrocyte autoantibodies cause myelin breakdown in MS.